System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Patrick Schöffski is an expert in Oncology at Universitair Ziekenhuis Leuven (Belgium). As of October 2026, ScienceLeadR ranks Patrick Schöffski in the top 1% of experts worldwide for Sarcoma and Gastrointestinal Neoplasms. Patrick Schöffski has authored 693 publications, the most recent in 2026, and is an investigator in 59 clinical trials, 6 of them ongoing. SLR score: 3,263 (community average: 125). How the SLR is computed.

LeadR Profile

Patrick Schöffski Universitair Ziekenhuis Leuven Belgium
3 263 ScienceLeadR Reputation 3263

Unlock

Register Login
Network Map

Oncology

Subspecialties: Endocrinology - Hematology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2026
Source: PubMed

Universitair Ziekenhuis Leuven

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 693

Citations

Citations: 56 703 1st author: 110 Last author: 145 Unique author: 12

Main journals

J Clin Oncol 148
Ann Oncol 83
Eur J Cancer 56
Cancer Res 44
Clin Cancer Res 27

Best Journals

J Clin Oncol 39
Ann Oncol 14
Lancet Oncol 9

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Nuclear grading of myxoid liposarcoma robustly predicts patient outcome: a study of 280 patients.
PMID 42873287 — cells, liposarcoma, neoplasms, pathology, biopsy, neoplasm metastasis, biopsy, needle, liposarcoma, myxoid, needles		Virchows Arch20260
Management of Soft Tissue and Visceral Leiomyosarcomas.
PMID 42720945 — radiotherapy, leiomyosarcoma, neoplasms, diagnosis, research, therapeutics, tissues		JAMA Oncol20260
Antitumor activity of novel transcriptional inhibitors ecubectedin and PM54 in soft tissue sarcoma patient-derived xenografts.
PMID 42600063 — pharmaceutical preparations, neoplasms, sarcoma, trabectedin, therapeutics, tissues, heterografts		Cancer Res Commun20260
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma.
PMID 42407248 — cells, safety, lymphoma, neoplasms, therapeutics, pharmacokinetics		Eur J Cancer20260
GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.
PMID 42387022 — cells, genes, neoplasms, polytetrafluoroethylene, therapeutics, t-lymphocytes, heterografts, car-t cell		Nat Cancer20263

Clinical Studies 59

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 3

By phase:

Phase 3 20
Phase 1 17
Phase 2 12
Phase 1/Phase 2 4
N/A 3
Phase 2/Phase 3 3

By status:

Completed 45
Recruiting 5
Terminated 5
Active not recruiting 2
Approved for Marketing 1
Unknown 1

By type:

Interventional 56
Observational 2
Expanded Access 1

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 7
multicentric5to9 7
multicentricup10 42

Main Topics

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
First in Human Study of ADCE D01 in Soft Tissue Sarcoma (ADCElerate 1)
2024-516900-41-00 — safety, dna topoisomerases, type i, sarcoma, topoisomerase i inhibitors, tissues, pharmacokinetics		Phase 1/Phase 2Recruiting2025
Public Title Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First line Treatment in Participants with Metastatic Leiomyosarcoma
2022-502975-45-00 — leiomyosarcoma, doxorubicin, therapeutics		Phase 3Active not recruiting2023
A study to test long term treatment with brigimadlin in people with solid tumours who took part in a previous study with this medicine
2024-514177-21-00 — safety, therapeutics		Phase 2Recruiting2024
A study to test the safety and efficacy of EP102 in patients with advanced solid tumours
2025-521305-40-00 — safety		Phase 1Recruiting2025
First in Human Study of ADCE D01 in Soft Tissue Sarcoma
NCT06797999 — safety, plasminogen, pharmaceutical preparations, plasminogen activators, dna topoisomerases, type i, sarcoma, topoisomerase i inhibitors, immunoconjugates, peptide hydrolases, urokinase-type plasminogen activator, receptors, urokinase plasminogen activator, therapeutics, tissues, pharmacokinetics		Phase 1/Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS